Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Submitted by Jeffrey Neal Johnson. Publication Date: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk already made me a “wealthy man”
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
Analyst Jim Rickards believes gold could climb to $10,000 per ounce or higher in the coming years - and he says investors still have time to position ahead of the move.
His top recommendation is a $2 stock he describes as sitting on the largest gold deposit in the world, with an extraction green light potentially arriving April 15. See Jim Rickards' number one gold recommendation for 2026
Abbott Laboratories’ stock price recently touched a 52-week low, closing just above $100 in late March. The sharp downturn has left many asking whether the foundation of this industry leader is cracking. A closer look at Abbott’s situation suggests a potential disconnect between market sentiment and operational reality. The key question for long-term investors is whether market pessimism is justified or if a significant value opportunity has emerged. Separating the Signal From the NoiseAbbott's decline can be traced to two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in Nutrition, primarily driven by market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has acknowledged the challenge and laid out a clear turnaround plan. CEO Robert B. Ford outlined price and promotion initiatives and at least eight new product launches planned for 2026, forecasting a return to growth in the second half of the year. The second factor is external and broader in scope: a rotation of capital across the market. In periods of economic optimism, investors often shift funds away from stable, defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in search of faster returns. That trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works through a short-term recovery, Abbott's core businesses remain robust—led by its largest and most profitable division, Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott's diversified model helps offset the isolated weakness in Nutrition, and the company's overall health is most apparent in these high-performing areas.
Medical Devices: This engine is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a growth phenomenon. The product line—which eliminates routine fingersticks—generated over $7.5 billion in sales in 2025 and remains a primary driver of Abbott's success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular care. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. This strength stems from a portfolio of best-in-class products, such as MitraClip and TriClip, and a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also pursuing strategic moves to secure future growth, including the acquisition of Exact Sciences. Exact Sciences is known for its non-invasive colon cancer test, Cologuard, and the deal would immediately position Abbott in the rapidly expanding market for cancer diagnostics. That acquisition would add a new, high-growth vertical to Abbott's portfolio and could become a meaningful contributor to revenue for years to come. Professional analysts tend to agree with this constructive view. Wall Street currently holds a Moderate Buy consensus rating on the stock. The average 12-month price target is $135.47, implying potential upside of over 30% from recent levels and suggesting many analysts view the stock as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is a compelling reason to take notice. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record underscores a strong commitment to returning capital to shareholders across market cycles. The recent drop in Abbott’s stock price has made its income more attractive to new investors: at current prices, Abbott yields about 2.5%, allowing investors to lock in a higher income rate from a historically reliable payer. The dividend appears secure: the payout ratio is roughly 68% of earnings but only about 37% of cash flow, indicating Abbott generates ample cash to cover dividends with room for future increases. A Disconnect Between Price and ValueMarket sentiment around Abbott seems disconnected from the company's business reality. Temporary headwinds in a single division and broad macro rotations have weighed on the stock, even as Abbott's fundamental growth engines—particularly Medical Devices and Diabetes Care—continue to accelerate. The dividend remains a dependable anchor, and strategic catalysts like the Exact Sciences acquisition could materially enhance growth. For investors with a long-term horizon, the current valuation highlights a noteworthy gap between price and fundamental value that merits serious consideration. |
No comments:
Post a Comment